Navigation Links
Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Date:10/5/2007

- Presentation to highlight milestones including phase III development of

'GI-friendly' NSAIDs for mild to moderate pain -

PALO ALTO, Calif., Oct. 5 /PRNewswire/ --

What: Horizon Therapeutics, Inc. is pleased to announce that

George Tidmarsh, M.D., Ph.D., chief executive officer, will

showcase Horizon's corporate and clinical milestones,

including its recent completion of Series C financing, and

provide an update on the development of the Company's

product pipeline during an Open House Podium Presentation

at BioPartnering Europe (BPE). Immediately following the

presentation Dr. Tidmarsh will be available to field

questions and provide more detailed information on Horizon

Therapeutics.

BPE was first held in London in 1993 as a partnership

between the U.S. Commercial Service and Technology Vision

Group LLC to bring about closer ties between American and

European biotechnology companies. From the beginning, BPE

has attracted the support of leading pharmaceutical,

biotechnology, financial and service companies that have

all contributed to making BPE one of the leading

independent partnering events in the world. BPE has a high

rate of sponsor retention, which indicates its prominent

position on the annual conference calendar for many

industry leaders.

When: Monday, October 8, 2007

9:30 a.m. - 12:45 p.m. Open House Podium Presentation

(10:45-10:55 a.m. Horizon presentation)

Where: London, England

QEII Conference Centre

Abbey Room West - Stream 1

Spokespeople: George Tidmarsh, M.D., Ph.D., co-founder and CEO of Horizon

Therapeutics

Barry Golombik, co-founder of Horizon Therapeutics

Contact: Julie Normart

WeissComm Partners

415.946.1087

jnormart@weisscommpartners.com

About Horizon Therapeutics:

Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, entered Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development. For more information visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New hope on the Horizon for People Wishing to Quit Smoking
2. A new horizon
3. Conjoined Indian Twins See Hope On The Horizon
4. Stem cell cure for peripheral vascular disease: New hope on the horizon
5. Oral Flu Vaccine On The Horizon In Russia
6. Rescheduled: Aerial Mosquito Treatment for Philadelphia
7. First Keyhole Heart Valve Surgery Scheduled in Britain
8. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
9. Researchers Present Ways To Reduce The Risk Of Dementia
10. Researchers Present Data Regarding The Efficiency Of Herbs
11. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... University Orthopedics (UOI) today announced ... of Hand, Upper Extremity and Microvascular Surgery at Newport Hospital. Dr. Bragdon specializes ... Orthopedics and Hand Surgery. , As the leader of comprehensive orthopedic care ...
(Date:3/22/2017)... ... 2017 , ... SNL Insurance and Financial, a Virginia based ... in the greater Hampton Roads area, is embarking on a community charity initiative ... , Each year, hundreds of people living in the South Hampton region are ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... assistance, and related services to families and business owners in the greater Nassau ... the Leukemia & Lymphoma Society. , Every 3 minutes, someone in America is ...
(Date:3/22/2017)... Toronto, CANADA (PRWEB) , ... March 22, 2017 , ... ... Indiegogo today, the Sweep&Stand. The conventional broom was great when it was invented, ... They are the working parents, the social young couple, the empty nesters and ...
(Date:3/22/2017)... ... ... The National Association for Business Resources (NABR) has recently named ... Wellness® companies for 2017. , American Specialty Health (ASH) was honored for ... its employees. ASH is one of only nine other San Diego companies being recognized ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... 2017 A new independent study demonstrates ... proven ultraviolet-C (UV-C) disinfection solution of choice for ... Published in the March issue of ... the peer-reviewed study of UV-C disinfection systems detailed ... Hospital and Rochester General Hospital. According to the ...
(Date:3/22/2017)... NEW YORK , March 22, 2017 ... Electrophysiology (EP) market is growing rapidly due to the ... a report published by Allied Market Research, the global ... is expected to reach $8.271 billion by 2022, with ... cardiology and is used to diagnose abnormal heartbeats or ...
(Date:3/22/2017)... ROCKVILLE, Md. , March 22, 2017 ... that should be important to those following the industry.  This ... point-of-care (POC) RSV test, and the POC testing market ... grow. An Alere subsidiary is facing a legal battle ... Meanwhile, Beckman Coulter launched a new chemistry ...
Breaking Medicine Technology: